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Abstract
Background: A protective malaria vaccine will likely need to elicit both cell-mediated and antibody responses. As
adenovirus vaccine vectors induce both these responses in humans, a Phase 1/2a clinical trial was conducted to evaluate
the efficacy of an adenovirus serotype 5-vectored malaria vaccine against sporozoite challenge.
Methodology/Principal Findings: NMRC-MV-Ad-PfC is an adenovirus vector encoding the Plasmodium falciparum 3D7
circumsporozoite protein (CSP). It is one component of a two-component vaccine NMRC-M3V-Ad-PfCA consisting of one
adenovector encoding CSP and one encoding apical membrane antigen-1 (AMA1) that was evaluated for safety and
immunogenicity in an earlier study (see companion paper, Sedegah et al). Fourteen Ad5 seropositive or negative adults
received two doses of NMRC-MV-Ad-PfC sixteen weeks apart, at 1610ˆ10 particle units per dose. The vaccine was safe and
well tolerated. All volunteers developed positive ELISpot responses by 28 days after the first immunization (geometric mean
272 spot forming cells/million[sfc/m]) that declined during the following 16 weeks and increased after the second dose to
levels that in most cases were less than the initial peak (geometric mean 119 sfc/m). CD8+ predominated over CD4+
responses, as in the first clinical trial. Antibody responses were poor and like ELISpot responses increased after the second
immunization but did not exceed the initial peak. Pre-existing neutralizing antibodies (NAb) to Ad5 did not affect the
immunogenicity of the first dose, but the fold increase in NAb induced by the first dose was significantly associated with
poorer antibody responses after the second dose, while ELISpot responses remained unaffected. When challenged by the
bite of P. falciparum-infected mosquitoes, two of 11 volunteers showed a delay in the time to patency compared to
infectivity controls, but no volunteers were sterilely protected.
Significance: The NMRC-MV-Ad-PfC vaccine expressing CSP was safe and well tolerated given as two doses, but did not
provide sterile protection.
Trial Registration: ClinicalTrials.gov NCT00392015
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Introduction
P. falciparum malaria causes 863,000 deaths and approximately
243 million cases annually and is a major infectious threat to non-
immune travelers to malaria-endemic areas[1]. Increasing drug
and insecticide resistance highlight the importance of developing
an effective malaria vaccine [2]. Sterile protective immunity
against malaria can be induced in animals or humans with
radiation-attenuated sporozoites, delivered by mosquito bite, that
invade hepatocytes, develop partially but are unable to transform
into blood stage parasites [3,4,5]. Protection appears to be species-
but not strain-specific, is sustained for at least nine months, and is
probably dependent on cell-mediated immunity (CMI) against
infected hepatocytes and antibodies against sporozoites
[6,7,8,9,10]. This model of protective immunity provides a
rationale for developing a vaccine inducing CMI targeting pre-
erythrocytic stages. On the other hand, naturally-acquired
immunity to malaria in humans appears to be dependent primarily
on antibody responses against blood stage antigens[11,12], with T
cell responses contributing[13,14], providing a rationale for
including blood stage antigens in a multi-stage vaccine.
NMRC-M3V-Ad-PfCA is a multistage adenovirus serotype 5
(Ad5)-vectored P. falciparum (3D7 strain) malaria vaccine contain-
ing two adenovectors mixed together for intramuscular delivery,
one encoding the circumsporozoite protein (CSP) and the second
the apical membrane antigen-1 (AMA1). The vaccine is designed
to reproduce the protective immune responses afforded by the
irradiated sporozoite vaccine (pre-erythrocytic stage immunity)
and by natural exposure (blood stage immunity). CSP, the major
surface protein of sporozoites, was chosen based on the ability of
the RTS,S vaccine, comprised of recombinant CSP, to elicit
protection in adults [15], children and infants [16] and due to
CSP’s contribution to the immunity induced by irradiated
sporozoites[17,18,19]. AMA1[20], expressed by sporozoites, liver
stages and merozoites[21,22,23,24], was selected because natural-
ly-acquired anti-AMA1 antibodies and proliferative responses are
associated with protection in endemic areas [25,26,27], recombi-
nant AMA1 protein is protective in non-human primates[28], and
has proven safe and immunogenic in Phase 1 studies in humans
[29,30,31,32,33,34].
Adenovirus-based vaccines may be better suited for inducing
immune responses which attack developing liver stage parasites
than recombinant proteins, based on their ability to induce
antigen-specific CD8+ T cells when administered either alone or
in heterologous regimens [35,36,37,38,39,40,41,42,43,44,45,46].
In contrast the RTS,S vaccine is thought to protect primarily via
antibody and CD4+ T cell responses to CSP, effectively targeting
the sporozoite[16,47,48,49], and does not appear to elicit
significant CD8+ T cell responses [50,51]. Recombinant attenu-
ated adenoviruses induce protection against malaria in animal
models[52], including adenovectors encoding CSP [53,54]. For
this reason, it seemed reasonable to determine whether an
adenovirus P. falciparum CSP vaccine alone would also be
protective in humans, before combining with AMA1, and before
combining with a heterologous vaccine in a prime-boost strategy.
In an initial clinical study, the safety of the parent, two-
component vaccine, NMRC-M3V-Ad-PfCA, was evaluated at two
doses in Ad5 seronegative volunteers (see companion paper
Sedegah et al, Groups 1 and 2). CD8+ T cell responses were
significantly stronger at the lower dose studied. In this second
clinical study (Group 3), the CSP component of the vaccine,
NMRC-MV-Ad-PfC, was evaluated at the lower dose for safety,
immunogenicity and protection against experimental sporozoite
challenge, enrolling both Ad5 seronegative and seropositive
volunteers. The trial demonstrated that the vaccine was safe and
well tolerated, but the second dose did not improve immunoge-
nicity over the first dose, and the vaccine did not sterilely protect
any volunteers.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
The Trial Protocol for the clinical trial presented in this
manuscript was approved by the National Naval Medical Center
(NNMC), Naval Medical Research Center (NMRC) and Walter
Reed Army Institute of Research Institutional Review Boards, in
compliance with all applicable federal regulations governing the
protection of human subjects. All study subjects gave written
informed consent. This study was conducted according to all
Federal Regulations regarding the protection of human partici-
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pants in research including The Nuremberg Code, The Belmont
Report, 32 CFR 219 (The Common Rule) and all pertinent
standards for the responsible conduct of research set by the
Department of Defense, the Department of the Navy, the
Department of the Army, the Navy Bureau of Medicine and
Surgery, the NNMC, the NMRC and the US Army Medical
Research and Materiel Command. NMRC holds a Department of
Defense/Department of the Navy Federal Wide Assurance for
human subject protections, and a Federal Wide Assurance from
the Office for Human Research Protections for cooperation with
the Department of Health and Human Services (FWA 0152). All
NMRC personnel were certified as having completed mandatory
human research ethics education curricula and training under the
direction of the NMRC Office of Research Administration and
Human Subjects Protections Program. The trial was performed
under US Food and Drug Investigational New Drug Application
BB-IND-13003.
Participants
Healthy malaria-naı¨ve civilian and military adult men and
women, age 18–50 years, were recruited for this study that was
conducted at the NMRC Clinical Trials Center in Bethesda,
Maryland. After obtaining informed consent, volunteers were
screened using inclusion and exclusion criteria similar to those
described in the companion paper (Sedegah et al). However, the
definition of ‘‘malaria naı¨ve’’ was refined for Part B of the study;
an exclusion criteria was added prior to the challenge to exclude
volunteers determined to have a greater than 10% five year risk for
a cardiovascular event based on the non-invasive cardiac
assessment tool outlined by Gaziano[55]. The Trial Protocol is
provided as part of the supplementary material.
Interventions
The vaccine, an adenovirus-derived construct expressing P.
falciparum strain 3D7 CSP (NMRC-MV-Ad-PfC), is described in
Sedegah et al (Groups 1 and 2). Immunization of Group 3 was
initiated in July 2008, five months after the final high dose
immunization with the parent vaccine. Fifteen volunteers received
the first dose and 14 the second dose. Each volunteer received
161010 particle units (pu)/mL. The dose of the CSP-encoding
construct was the same as the dose of CSP-encoding construct in
Group 1 in Sedegah et al (Table 1).
Objectives
The first objective was to assess the safety and tolerability of the
NMRC-MV-Ad-PfC vaccine. The second objective was to assess
the immunogenicity of the vaccine, including the effects of Ad5
seropositivity. The third objective was to assess the protective
efficacy against sporozoite challenge, enabling historical compar-
ison with the protection afforded by RTS,S.
Outcomes
The methods used to evaluate safety, tolerability and reactoge-
nicity were very similar to those described in the companion
paper, Sedegah et al. For this part of the study, safety assessments
were recorded by direct observation and questioning on days 1, 2,
3, 5, 7, 14 and 28. The final study visit was approximately 1 year
after the second immunization. Local, systemic, and laboratory
AEs were graded using severity scales detailed in the Trial Protocol
(Sedegah et al, supplementary material). Telephone or email
follow-up for all study subjects is to extend for a total of five years
per FDA request.
Sample size
The sample size was based on many years of experience
conducting malaria vaccine trials at NMRC and WRAIR and was
designed to demonstrate the vaccine’s safety and tolerability profile
in a small number of volunteers to provide evidence that the
frequency of serious or severe vaccine-related AEs was sufficiently
low to continue testing in larger numbers of volunteers. If none of
the targeted twelve immunized volunteers experienced a serious or
severe vaccine-related AE, the following predictions could be
made regarding vaccine safety: there was a 46% level of
confidence that the true rate of severe or serious vaccine-related
AEs in the general population would be less than 5%;
alternatively, there was a 72% level of confidence that the true
rate of these events in the general population would be less than
10%; or, as a third example, there was a 93% level of confidence
that the true rate would be less than 20%. These figures were
determined using the exact binomial method (1-p) n = 1-c where p
is the probability that a subject has an event, n is the total number
of subjects and c is the level of confidence. In addition the sample
size was powered to detect a two day mean delay in patency in the
immunized group compared to the infectivity controls (80%
power, a= 0.05, one-sided) [15].
Immunological endpoints
Immunological measurements were performed pre-immuniza-
tion, 1 month and 15 weeks after the first immunization, 19 days
after the second immunization, and 3 weeks after challenge.
Ex vivo Enzyme-Linked Immunospot (ELISpot) IFN-c
activity. This was performed as described in Sedegah et al.
Table 1. Vaccine constructs, doses, and times of immunization.
Vaccine Trial Group (n) Particle units (pu) per dose # doses Total dose (pu)
CSP AMA1 Total
NMRC-M3V-Ad-PfCA (CSP & AMA1 mixed) 1 1 (6) 161010 161010 261010 1 261010
2 (6) 561010 561010 161011 1 161011
NMRC-MV-Ad-PfC (CSP only) 2 3 (15) 161010 0 161010 2 261010
Trial 1: Dose escalation study: Group 1 was immunized with a single dose, a safety review was conducted, then Group 2 was immunized with a single five-fold higher
dose. Results are presented in the companion publication, Sedegah et al.
Trial 2: Challenge study. Group 3 was immunized twice using the Group 1 dose of CSP, with 15 weeks between doses. Fifteen volunteers received the first dose, 14
volunteers the second; data for all 29 immunizations are included in the safety analysis. Twelve volunteers underwent malaria challenge 21 days following the second
immunization; one of the 12 was later excluded from the analysis of immunogenicity and protection due to the discovery of prior participation in another malaria
challenge trial.
doi:10.1371/journal.pone.0025868.t001
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Stimulants were pools of 15 amino acid (aa) synthetic peptides
overlapping by 11 aa (Chiron Technologies, Clayton, Victoria,
Australia) covering full length CSP. These were combined into 9
CSP pools (Cp1-Cp9) containing 3-12 peptides per pool (Table 2),
with pools used individually as stimulants for fresh PBMCs. Each
pool (except Cp2) contained previously identified CSP T
epitopes[56,57,58]
Intracellular cytokine staining (ICS). For each volunteer,
matched pre- and post-vaccination samples were tested
simultaneously using frozen PBMCs. ICS was performed as
published previously [38] and is described in Sedegah et al.
Enzyme-Linked Immunosorbent Assay (ELISA). ELISA
was used to measure total IgG antibody titers against the P.
falciparum CSP central repeat region using a hexameric synthetic
peptide (NANP)6 as the capture antigen as described in Sedegah et
al. A positive antibody response required that the means of the
post-immunization antibody responses (endpoint titers) differed
significantly from pre-immunization responses (P,0.05) using the
paired Student’s two-tailed t-test [59].
Immunofluorescent Antibody Assay (IFA). P. falciparum
sporozoite-specific antibodies were assayed by immunofluorescent
staining of air-dried P. falciparum sporozoites as described
previously[60].
Adenovirus serotype 5 neutralization assay. This test was
performed under contract by the NIAID Vaccine Immunogenicity
T-cell and Antibody Laboratory (NVITAL), Gaithersburg, MD.
Sera that had been heat inactivated for 60 minutes at 56uC were
serially diluted in a final sample volume of 50 mL D10 (Dulbecco’s
modified Eagle’s medium supplemented with 10% heat
inactivated fetal bovine serum, penicillin 100 U/mL, and
streptomycin 100 mg/mL). To each well 50 mL of the optimized
dilution of rAd5-luciferase was added, followed by addition of
16104 A549 cells (human lung carcinoma)/well in 100 mL D10.
The plates were incubated at 37uC in 10% CO2 for 24 hours.
After centrifugation to pellet the cells they were resuspended in
100 mL Glo Lysis Buffer. The cell suspension was transferred to a
Black and White Isoplate (Perkin Elmer) and 100 mL Steady-Glo
Luciferase Assay System Reagent (Promega) added per well.
Following incubation at room temperature for 15-minutes
luminescence was measured on a luminometer. The 90%
inhibition serum titer was determined to be that serum dilution
which could be interpolated to have 10% of the maximum
luciferase activity as determined by the assay run without the
presence of a serum sample.
Efficacy
Protective efficacy was assessed by conducting a homologous
3D7 strain sporozoite challenge 3 weeks after the second NMRC-
MV-Ad-PfC immunization. Twelve vaccinated and 6 unvaccinat-
ed volunteers (infectivity controls) underwent a standardized
challenge as previously described [61]. Starting on day 7 after
challenge, volunteers were housed at the Navy Lodge on the
NNMC campus in Bethesda, MD. Each volunteer was monitored
for the onset of signs and symptoms of malaria and by daily
Giemsa-stained thick blood films with positive films confirmed by
a second reader. The identity of immunized and non-immunized
volunteers was known to the clinical trial staff but not to the
microscopists reading the malaria smears. Symptomatic, undiag-
nosed volunteers had additional smears performed at the
discretion of the study doctor, not to exceed one smear every 8–
12 hours. Volunteers who developed malaria (as defined by a
positive blood smear) were treated with a standard oral dose of
chloroquine: total 2500 mg base given in divided doses: 1000 mg
initially followed by 500 mg at 6, 24 and 48 hours under direct
observation.
Table 2. CSP peptides used in ELISpot and ICS assays.
Pool CSP aa # Pep* Class HLA restriction Residues Sequence**
1+ 1–39 7 I A2.1 supertype 1–10 MMRKLAILSV
I A2 supertype 7–16 ILSVSSFLFV
II DR (A2.1 and A2 supertype) 1–20 MMRKLAILSVSSFLFVEALF
2+ 29–71 8
3 61–107 9 I B8 81–89 KLRKPKHKK
4 97–283 12 II DR 105–116 NANPNVDPNANP
5 273–319 9 II DR (B7) 281–300 QGHNMPNDPNRNVDENANAN
I B7 86–94 MPNDPNRNV
6+ 309–331 3 I A1 310–319 EPSDKHIKEY
I A2.1 319–327 YLNKIQNSL
II DR (A2.1) 316–335 IKEYLNKIQNSLSTEWSPCS
7 321–335 6 II Th2r 326–343 SLSTEWSPCSVTCGNGIQ
8 345–367 3 II B35-Th3r 346–365 IKPGSANKPKDELDYANDIE
9+ 357–397 8 II DR 363–383 DIEKKICKMEKCSSVFNVVNS
II DR (A2 supertype) 375–397 SSVFNVVNSSIGLIMVLSFLFLN
I A2 supertype 386–394 GLIMVLSFL
PfCSP peptide sequences and residue numbers were based on those of the P. falciparum clone 3D7 (GenBank no. X15363). Previously identified Class I and II CSP
epitopes were distributed among peptide pools, except pool 2.
**Previously identified T epitopes.
*Number of 15mer peptides in each pool.
**As described in references 55–57.
+Peptide pools used in ICS assays.
doi:10.1371/journal.pone.0025868.t002
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Microscopy. 10 ml of blood was smeared onto each of two
1 cm62 cm rectangles on each slide. The slides were dried on a
37uC heat block for 5–10 minutes. Slides were stained with fresh
Giemsa stain (4% solution of stain in phosphate buffered water) for
45–60 minutes, rinsed with water and allowed to dry. The slides
were viewed under oil immersion at a total of 1000x
magnification. For asymptomatic individuals, 360 fields were
counted in five vertical passes. For symptomatic individuals, 1080
fields were counted in approximately 15 vertical passes. A
volunteer was determined to be parasitemic when at least two
parasites were found and confirmed by an expert microscopist.
The physician on duty was informed by the microscopist of the
volunteer’s status and personally observed the confirmed parasites.
Parasitemia was calculated from the number of parasites observed
in five passes (0.45 mm3) multiplied by 2.22 to give parasites/ml.
The expert microscopist had extensive experience in malaria
microscopy and all microscopists passed a proficiency test on slide
parasite detection.
Statistical methods
ELISpot activities were expressed as sfc/m and as the geometric
means of each group. ELISA and IFA activities were expressed as
titers and as the medians of each group. Variation in ELISpot
counts, ELISA measurements, IFA measurements and flow
cytometry data over time within groups was examined using
repeated measures models. ELISpot, ELISA and IFA, but not flow
cytometry, data were transformed to logarithms for analysis to
stabilize variances. Linear contrasts were employed to compare
specific time points if variation over time was detected. Repeated
measures models were also employed to compare trends over time
among Groups 1, 2 and 3. The initial model in each analysis
included the group, a categorical variable for time, and the group-
time interaction as predictors. The interaction provided a test for
differences among groups in changes over time. The interaction
was dropped if it was not statistically significant. Tests for variation
over time and differences between groups were based on the
reduced model. A statistically significant interaction was followed
by more detailed analysis. If the initial analysis involved all three
groups, then the analysis was repeated for each of the three pairs of
groups to elucidate the reasons for the interaction. The same
approaches were used to examine trends in log-transformed Ad5
neutralizing antibodies within each of three subgroups and to
compare trends among the subgroups, with the subgroups defined
by baseline neutralizing antibody titer (,12, $12 but #500,
.500).
Time to parasitemia in the vaccinated subjects and controls was
compared using Kaplan-Meier survival curves with a log-rank
statistic. For each vaccinated volunteer, delay to parasitemia was
defined as significantly positive if the time to parasitemia was 2
standard deviations greater than the geometric mean of the time to
patency of the controls[49]. Rank correlations were employed to
examine the relationships between Ad5 neutralizing antibodies
and measures of immunogenicity. The number of AEs reported
per subject was compared between groups using the Wilcoxon two
sample test to compare Group 1, Group 2 (Sedegah et al) and
Group 3, or the three subgroups defined by Ad5 neutralizing
antibody titer (#12, 12–500, .500).
Results
Participant flow
The participant flow is shown in Figure 1. Recruitment for
Group 3 took place between February and June 2008 for the
immunization phase and between July and November 2008 for the
challenge phase (enrolment of six infectivity controls). Seventy-
nine healthy, malaria-naı¨ve, civilian and military adult men and
women were recruited and screened for eligibility in a manner
similar to that used for Groups 1 and 2 except volunteers with pre-
existing NAb to Ad5 were included. Twenty-one volunteers who
met all screening criteria participated as vaccine recipients (n = 15)
or as infectivity controls (n = 6). One volunteer withdrew prior to
the second immunization due to schedule conflicts, another
volunteer withdrew prior to the challenge due to schedule
conflicts, and a third volunteer was withheld from the challenge
due to safety concerns related to a Grade 3 headache experienced
following the second immunization (see below). Therefore 15
volunteers received the first immunization, 14 the second, and 12
participated in the malaria sporozoite challenge. Of these 12, one
was excluded after challenge from the immunogenicity and
efficacy analyses but not safety analyses when it was discovered
that he had been a participant in a previous malaria vaccine study
and therefore may have possessed a degree of immunity to
malaria. In total, the NMRC-MV-Ad-PfC vaccine was adminis-
tered as 29 doses to 15 volunteers at 161010 pu. The demographic
make-up of the participant volunteers is shown in Table 3. The
vaccine groups and infectivity controls were similar in age and
ethnicity.
Local and systemic adverse events
Solicited post-immunization AEs recorded in each 14-day
follow-up period are shown in Table 4. The only reported local
AEs were pain and/or tenderness at the injection site, which
occurred in ten of 15 (67%) of the volunteers following the first
immunization and in 12 of 14 (86%) of the volunteers following
the second immunization. The majority of these were of moderate
severity. No adenopathy was recorded, although ipsilateral axillary
tenderness was noted in one volunteer following the first
immunization. There were no Grade 3 local AEs following either
immunization.
The most common systemic vaccine-related AEs following the
first immunization were malaise and myalgia, each occurring in
two of 15 (13%) volunteers, and following the second immuniza-
tion, fatigue, headache, nausea and/or vomiting, each occurring
in two of 14 (14%) volunteers. Systemic events following both the
first and second immunization were mostly of mild severity.
One Grade 3 AE was reported, a headache that began
approximately 8 hours following receipt of the second immuniza-
tion in a volunteer with a history of migraine headaches. The
headache was associated with photosensitivity and sound sensitiv-
ity, typical for this volunteer’s migraine headache pattern. The
volunteer also experienced 3 episodes of moderate (Grade 2) chills
during the headache, occurring 12–13 hours following the second
immunization. The chills were not a typical component of this
volunteer’s migraine pattern. The volunteer reported prompt relief
of the headache and associated symptoms on taking prescribed
migraine medication. The event was deemed possibly related to
the vaccine and the volunteer was excluded from the malaria
sporozoite challenge.
Because of the theoretical, even if remote, possibility of
reversion of the vaccine to replication competence, attention was
paid to symptoms that might have reflected adenovirus infection.
Several volunteers experienced clinical syndromes of mild or
moderate severity consistent with adenovirus infection, including
conjunctivitis, enteritis, nasal congestion, pharyngitis and upper or
lower respiratory infections (see also Table S1: Unsolicited
Adverse Events), but the timing relative to immunization was
variable suggesting that these were probably not related to
immunization. The rate of occurrence of these miscellaneous
Ad5-Vectored falciparum Malaria Vaccine (CSP)
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25868
clinical syndromes appears consistent with background infections
circulating in the community during the periods of immunization.
Comparing Groups 1, 2 and 3
To more closely investigate whether there was a relationship
between dose of the adenovector and AE severity, we examined
the differences among the three groups of volunteers receiving the
vaccine (see Sedegah et al). As derived from Table 4 the
frequencies per volunteer of four common AEs (injection site pain
or tenderness, malaise, headache and myalgia) and of fever were
compared (Figure 2). On average, subjects in high dose Group 2
(Sedegah et al) reported the greatest number of AE’s (Grade 1:
1.0/volunteer, Grade 2: 1.0/volunteer, Grade 3: 0.33/volunteer),
while those after the first immunization in Group 3 (this study)
reported the fewest (Grade 1: 0.4/volunteer, Grade 2: 0.6/
volunteer, Grade 3: 0.00/volunteer). Although the differences
were not statistically significant using the Wilcoxon two sample test
after the first (p = 0.08) or second (p = 0.10) immunizations in
Group 3, the trends in these differences among groups were
consistent with the varying doses of adenovector received: Group 2
received 5-fold more per dose than Group 1, and 10-fold more
than Group 3.
Effect of pre-existing anti-Ad5 antibodies and adverse
events
Although pre-existing anti-Ad5 antibodies have been reported
to reduce the incidence of AEs in some clinical trials of adenovirus
vectored vaccines[62], there was no association between pre-
existing anti-Ad5 antibody titer and the sum of local and systemic
AEs (Pearson Correlation p = 0.70, 2-sided). The second immu-
nization was excluded from the analysis because all subjects
became seropositive after the first immunization.
Unsolicited adverse events
Volunteers were questioned for unsolicited symptoms for 28
days following vaccine administration by being asked ‘‘are you
experiencing any additional symptoms?’’ Their unsolicited AEs
are listed in Table S1. The unsolicited AEs considered definitely or
probably related to immunization were: burning (n = 1), numbness
(n = 1) or bruising (n = 2) at the injection site.
Figure 1. Flow diagram of volunteers (Group 3). * Reasons for exclusion: Moved out of area (3), deployed (2), lost to follow up (2), opted out (1),
eligible but preferred waiting for follow-on study (12). ** The first 15 volunteers were allocated to the vaccine group and the final six volunteers to
infectivity controls. *** 11 volunteers analyzed for immunogenicity and protection; 15 analyzed for safety of dose 1, 14 for safety of dose 2.
doi:10.1371/journal.pone.0025868.g001
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Laboratory adverse events
In response to the transient falls in white blood count seen in
Groups 1 and 2, the Trial Protocol for Group 3 was amended to
include more frequent collection of safety labs during the first week
post immunizations namely days 0, 1, 2, 3, 5 and 7. As an
unrelated change, the chemistry panel was reduced in scope, to
only include creatinine, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT). As in Groups 1 and 2, an overall
decrease in WBC, neutrophil and lymphocyte counts occurred in
the majority of the volunteers within the first 3 days after receiving
the vaccine (Figure 3). Within 14 days after the first immunization,
Grade 1 neutropenia was recorded in one of 15 volunteers and
Grade 2 in one of 15 volunteers; within 14 days after the second
immunization, Grade 1 neutropenia was recorded in two of 14
volunteers and Grade 2 in two of 14 volunteers.
In general the decrease in lymphocytes occurred earlier than the
decrease in neutrophils (day 1 compared to day 2 or 3) (data not
shown). After immunization one, three volunteers had elevated
AST and/or ALT; all were Grade 1 except for a Grade 2 ALT in
one volunteer. After immunization two, four volunteers had
elevated AST and/or ALT; all were Grade 1. A few volunteers
had mild abnormalities on urinalysis. No other laboratory trends
were noted.
Immunogenicity
Cell mediated and antibody responses were measured pre-
immunization, 1 month and 15 weeks after the 1st immunization,
19 days after the 2nd immunization (2 days prior to challenge) and
21 days after challenge.
T cell responses to CSP by ex vivo IFN-c ELISpot
Assay. All 11 volunteers developed increasing responses to
CSP following the first immunization, as measured by fresh, ex vivo
(36 hour stimulation) ELISpot assay (seven of 11 meeting criteria
for positive–see Methods, Sedegah et al), with the responses of nine
peaking at 4 weeks and then drifting down by 15 weeks, while two
(v52 and v68) had higher responses at 15 weeks than at 4 weeks
(Figure 4). Geometric mean responses at 4 weeks were 323 sfc/m,
range 71–1127 sfc/m, and decreased by 15 weeks to 152 sfc/m,
range 63–320 sfc/m. All volunteers but one (v52) again developed
increasing responses to CSP by ELISpot assay following the
second immunization (nine of 11 meeting criteria for positive), but
in seven of 11 cases the peak response following the second
immunization was less than the peak observed following the first
immunization. Geometric means at 19 days after the second
immunization were 247 sfc/m, range 127–552 sfc/m. When the
group was examined as a whole, there was a statistically significant
increase in ELISpot responses with each immunization (p,0.0001
for the first and p = 0.02 for the second immunization, ANOVA),
but there was no difference between the peak responses following
the two immunizations (p = 0.22, ANOVA) (Figure 4 insert). V45
was the weakest responder by ELISpot (one of two volunteers not
meeting criteria for a positive response) and also by ELISA and
IFA (see below). Volunteers responded to a variety of peptide
pools, with Cp1, Cp2, Cp6 and Cp9 inducing the strongest recall
responses overall, as was the case for Groups 1 and 2. At least
three volunteers showed boosting of ELISpot responses following
challenge (v40, v52 and v69) but others did not, and overall group
responses were unchanged following challenge.
Total-IFN-c (T- IFN-c) responses to CSP peptides by
intracellular cytokine staining (ICS). Multi-parameter flow
cytometry ICS assays were conducted on frozen PBMC at the
same time points as fresh ELISpot assays using the four CSP
peptide pools most strongly stimulating recall responses in
ELISpot assays (Cp1, Cp2, Cp6 and Cp9). Results are expressed
as percentage gated CD4+ or CD8+ T cells secreting IFN-c after
subtraction of pre-immunization values (Figure 5). As with Groups
1 and 2 ELISpot activities, overall CD8+ T cell IFN-c responses
were significantly stronger than CD4+ T cell IFN-c responses
(p = 0.026), despite the fact that two volunteers (v058 and v065)
showed stronger CD4+ T cell responses. Overall, there were
numerically more IFN-c-secreting CD8+ T cells that CD4+ T cells
even after correcting for the larger number of gated CD4+ T cells
(data not shown).
As with ELISpot, the ICS responses of most volunteers peaked
four weeks after the first immunization (geometric means CD8+
0.09% range 0.012–0.556%, CD4+0.039% range 0.00141–
0.137%), fell during the ensuing 11 weeks, and were then boosted
by the second immunization (geometric means CD8+ 0.046%
range 0.001–0.512%, CD4+ 0.021% range 0.0081–0.1338%) but
generally not to the levels achieved after the first immunization;
however, a few volunteers’ responses were higher after the second
immunization compared with after the first. Overall geometric
mean IFN-c responses were not statistically different after the
second immunization compared with after the first immunization
for CD4+ or CD8+ T cells (Figure 5). Responses following
challenge varied among volunteers, some rising and some falling,
and overall there was no statistically significant difference from
values prior to challenge.
Multifunctional T cell responses to CSP. In addition to
IFN-c responses, TNF-a and IL-2 responses were measured,
including the frequencies of CD4 and CD8 T cells producing only
these cytokines or these cytokines in combination with others
(multifunctional T cells). The frequencies of multifunctional cells,
defined as those producing two or more cytokines, at 1 m are
shown in Figure S1. As was seen in Groups 1 and 2, the
frequencies of CD8+ and CD4+ multifunctional T cells were
similar after the first immunization (geometric means CD8+
Table 3. Demographics of volunteers.
Immunized N=15 Controls* N=6
Male # 11 3
Female # 4 3
Age range 18–20 years 0 0
Age range 21–30 years 4 2
Age range 31–40 years 6 1
Age range 41–50 years 5 3
Overall age range years 21–50 26–48
Median age years 36.5 40.0
Mean age years 35.9 38.0
Caucasian # 4 5
African American # 8 1
Hispanic # 1 0
Asian # 2 0
Individual Ad5 NAb titers ,12, 12, ,12
,12, 82, 114,
157, 615, 5068
.8748,
.8748**
Not applicable
*Infectivity controls.
**NAb = neutralizing antibody titers for Ad5 (provided only for the 11
volunteers included in the immunogenicity and efficacy analysis).
doi:10.1371/journal.pone.0025868.t003
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0.014% range 0.001–0.087, CD4+ 0.015% range 0.00120.0631),
and this was also true after the second immunization (geometric
means CD8+ 0.008% range 0.00120.196, CD4+ 0.011% range
0.00120.089). Pool-specific multifunctional responses were
examined and the geomeans showed similar magnitudes for
CD4+ and CD8+ T cells (p = 0.8), with a great deal of variation
among individual vaccine recipients especially for multifunctional
CD8+ T cells (Figure S1).
All CD4+ and CD8+ T cell cytokine subsets were measured and
the arithmetic means and standard deviations of each are shown in
Figure 6. Overall, CD8+ T cells secreting only IFN-c were the
dominant phenotype across all categories. The different cytokine-
secreting groups remained relatively constant as a proportion of
total CD4 or CD8+ T cells during the course of the trial with no
evidence of strongly changing ratios following the second
immunization or immediately after challenge. An exception was
CD4+ T cells secreting only IL2, a phenotype that rose after the
second immunization, with total IL2 exceeding total IFN-c at this
time point. In addition, total CD8+ T cell IL2 and TNF-a also
rose after the second immunization, but remained below total
CD8+ T cell IFN-c. Interestingly, measurements taken at a late
time point – 12 weeks post challenge – showed that CD8+ and
CD4+ T cell IFN-c responses were sustained.
Antibody responses. In general, anti-CSP antibody
responses as measured by ELISA and sporozoite IFA were low
following immunization, with the majority of titers recorded at less
than 1:1000 (Figure 7). Responses by ELISA peaked 4 weeks after
the first immunization in six of 11 volunteers with exceptionally
strong responses in one (v58), and at 15 weeks in one of 11
volunteers (v63), with negligible responses in four volunteers (v45,
v52, v65 and v66). Patterns for IFA were similar. After the second
immunization at week 16, titers rose in eight volunteers by each
assay and showed little change for three volunteers; of the
volunteers responding to the second immunization, only v63
significantly (by .2 fold) exceeded titers achieved after the first
immunization. Thus, titers were similar for ELISA and IFA
Table 4. Number (percent) of volunteers experiencing solicited local and systemic adverse (definitely, probably or possibly related
to immunization).
Sign or Symptom 1
st Imm (n=15) 2nd Immun (n=14)
All Gr 3 All Gr 3
LOCAL
Pain/tenderness 10(67) 0 12 (86) 0
Erythema 0 0 0 0
Induration/swelling 0 0 0 0
Warmth Ns - 0 0
Hives Ns - 0 0
Lymphadenopathy 0 0 0 0
Limited arm motion Ns - 0 0
Axillary tenderness 1 (7) 0 0 0
MEAN{ LOCAL 0.7 0 0.9 0
SYSTEMIC
Fever (objective) (((O((objective)(objective) 0 0 0 0
Fever (subjective) 1 (7) 0 0 0
Headache 1(7) 0 2(14) 1(7)
Malaise 2(13) 0 1(7) 0
Fatigue 1(7) 0 2(14) 0
Myalgia 2(13) 0 1(7) 0
Arthralgia 0 0 0 0
Nausea/vomiting 0 0 2(14) 0
Diarrhea 1(7) 0 1(7) 0
Pink eye/conjunctivitis D 0 0 1 (7) 0
Nasal congestion 1 (7) 0 0 0
Dysuria 0 0 0 0
Pharyngitis ns* - 1 (7) 0
Eye pain/irritation ns* - 1 (7) 0
Dizziness ns* - 1 (7) 0
Chills ns* - 1(7) 0
MEAN{ SYSTEMIC 0.6 0 1.0 0.1
Solicited adverse events were recorded for 14 days after each immunization. Gr = severity grade.
{Mean number per volunteer per immunization.
*Not solicited (ns) after first immunization, but added to the list of solicited symptoms after second immunization. The following were also added for the second
immunization with negative responses by all volunteers: pruritis, rash, cough, coryza, and urinary frequency.
doi:10.1371/journal.pone.0025868.t004
Ad5-Vectored falciparum Malaria Vaccine (CSP)
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25868
comparing after the first to after the second immunization (ELISA
median 300 range 70–3579 after the first, and median 150 range
59–1980 after the second immunization; IFA median 320 range
10–2560 after the first, and median 320 range 40–5120 after the
second immunization). Therefore, as with ELISpot, when the
group was examined as a whole, there were no significant
differences in humoral responses comparing the two
immunizations (p = 0.42 for ELISA, 0.89 for IFA), even though
there was a statistically significant increase in ELISA and IFA
responses compared to pre-immunization titers with each
immunization (p = 0.0001 for the first and 0.0398 for the second
immunization for ELISA, and p = 0.0018 and 0.0177 for IFA). As
with ELISpot, challenge had little effect on CSP ELISA titers in
the group as a whole, while there was a statistically significant
boosting of IFA titers (p = 0.02), indicating increased antibodies to
the whole sporozoite, as would be expected following malaria
infection.
Antigen interference: comparison of antibody and
ELISpot responses to NMRC-MV-Ad-PfC and NMRC-M3V-
Ad-PfCA. Group 3 offered the opportunity to look for inter-
ference between CSP and AMA1, since the CSP component of the
vaccine, NMRC-MV-Ad-PfC, was administered in combination
with the AMA1 component, NMRC-MV-Ad-PfA, to the volunteers
in Group 1, and then was administered by itself, at the same dose, to
volunteers in Group 3 (Figure 8). Combination with AMA1 in
Group 1 did not reduce the immunogenicity of CSP by ELISpot
(Group 1: geometric mean 422 sfc/million range 114–1066 sfc/m;
Group 3: 323 sfc/million range 71–1127 sfc/m), ELISA (median
Group 1 titer: 692 range 567–886; Group 3 titer: 300 range 70–
3579), IFA (median Group 1 titer: 960 range 320–1280; Group 3
titer: 320 range 10–2560). Although not statistically significant, the
trend was for improved responses when in combination, rather than
diminished responses. This suggests that the adenovector backbone
itself may have provided a degree of non-specific immune
stimulation, since volunteers in Group 1 received twice the dose
of adenovector as volunteers in Group 3 due to inclusion of the
AMA1 component in Group 1.
Comparisons of low dose Groups 1 and 3 with high dose
Group 2. For comparison purposes, Figure 8 includes ELISpot,
ELISA and IFA responses to CSP for Group 2, which received a
five-fold higher dose of NMRC-MV-Ad-PfC than Groups 1 or 3.
ELISpot responses in Group 2 were significantly lower than in
Group 1 (p = 0.0189) or Group 3 (p = 0.0009) when examined
over the three time points, while ELISA and IFA responses in
Group 2 trended higher than in Groups 1 or 3.
Correlations among immune responses. Immune res-
ponses were log10 transformed in order to conduct correlation
analyses. CSP ELISA and sporozoite IFA responses were closely
correlated with each other after the first immunization (correlation
coefficient[r] = 0.826, p = 0.0017) and after the second
immunization (r = 0.787, p = 0.004), as would be expected given
that CSP is the dominant surface antigen of sporozoites. Neither
antibody assay correlated with ELISpot responses (r,0.51,
p.0.10 for each correlation), although interestingly all three of
the volunteers whose ELISA titers never exceeded 100 (v045,
v052, v066) were also low responders by ELISpot assay. The
ELISA responses following the first and second immunizations
were significantly correlated with each other (r = 0.666, p =
0.0252), and the same was true for IFA (r = 0.632, p = 0.0370) and
for ELISpot (r = 0.738, p = 0.0095).
Although measuring different cell populations, ELISpot and
ICS assays generally showed concordance. This was determined
by comparing the dominant peptide pool as measured by ELISpot
assay (Figure 4) and as measured by flow cytometry (Figure 5) for
CD8+ T cells on day 28 after the first immunization. Discounting
the low ELISpot responders (v045 and v068), in all other cases the
dominant pool by ELISpot (or in the case of v063, one of the three
equally dominant pools–see Figure 4) was also the dominant pool
for CD8+ T cells by ICS assay (Figure 5), the only exception being
v058 for which CD4+ T cell responses were stronger than CD8+
Figure 2. Frequency of Selected Adverse Events Recorded from Day of Immunization through 14 days post-immunization for
Groups 1, 2 and 3. The frequencies of pain, malaise, headache and myalgia (combined) by severity grade, and, separately, of objective fever (one
grade 1 and one grade 2) are shown for each vaccine group.
doi:10.1371/journal.pone.0025868.g002
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T cell responses and for whom the dominant pool for CD4+ T
cells responses was concordant with the dominant pool for
ELISpot responses.
Efficacy
Twelve volunteers who completed both immunizations and
were cleared from a safety perspective, plus 6 non-immunized
infectivity controls, underwent malaria challenge by the bite of five
P. falciparum-infected mosquitoes on day 21 following the second
dose of vaccine. All 12 completed the challenge and follow-up, but
one volunteer was removed from the analysis due revelation of
previous participation in a malaria vaccine trial (information not
disclosed at the time of enrollment). Therefore 11 volunteers were
analyzed for immunogenicity and protection.
The challenge outcome is shown in Figure 9. There was no
sterile protection as all volunteers developed parasitemia. The
unimmunized infectivity controls became patent on days 12 (3/6)
and 14 (3/6). The immunized volunteers became patent on days
12 (5/11), 13 (1/11), 14 (2/11), 15 (1/11) and 16 (2/11). There
was no significant delay to parasitemia in the immunized group
compared with the control group (Log Rank test: p = 0.46). The
geometric means of time from infectious bite to patency were
similar: immunized: 13.37 days, SD 1.63 days and controls: 12.96
days, SD 1.10 days. However, 2/11 immunized volunteers
became patent on day 16, more than 2 standard deviations after
the geometric mean of the time to patency for the controls
(12.96+[261.10] = 15.1 days) indicating that these two volunteers
(v45 and v69) had a delay in developing parasitemia. The NAb
titers for v45 prior to the first and second immunizations were 82
and 924, respectively, and for v69 were ,12 and 3600,
respectively – thus one volunteer was considered seronegative at
the time of first immunization (titer #12) while a second was
considered low seropositive (.12 to 500).
Pre-existing and vaccine-induced anti-Ad5 NAb
responses
For analysis, volunteers were divided into three groups:
seronegative NAb.12; low levels NAb 12-500; and high levels
NAb.500. Of the 11 volunteers assessed for immunogenicity and
protection, four were Ad5 seronegative (v58, v61, v65 and v69),
three had low levels of NAb (v41, v45, v68) and four had high
levels (v40, v52, v63 and v66) at the time of screening (Table 3).
The cut-off of 500 in the NVITAL assay is equivalent to the cut-off
of 200 in the Merck assay [63]. The first dose of NMRC-MV-Ad-
PfC induced NAb in volunteers who had been seronegative
(median 4243, range 714-6317), and boosted pre-existing NAbs in
volunteers who had low levels of NAb (median 5252, range 848–
7285), and in volunteers with high levels of NAb (median, 30700,
range 3893–177600) (Figure 10, right panel). After the second
immunization, the majority of volunteers (nine of 11) developed
responses that further exceeded activities after the first immuni-
zation (median titers seronegatives 20400 range 4142–23700, low
seropositives 27900 range 5403–38100; and high seropositives
42300 range 8400–176100). The increases over time were highly
significant for the seronegative and intermediate baseline groups
(p,0.0001, p = 0.0026, respectively) but not for the initially high
baseline group (p = 0.23).
Effect of pre-existing and vaccine-induced anti-Ad 5 NAb
on anti-CSP antibody and CMI responses
To examine the effect of NAb on immunogenicity, NAb titers
prior to the first immunization were tested to determine if
correlations existed with IFN-c ELISpot counts, CD4+ T cells
secreting IFN-c by ICS, CD8+ T cells secreting IFN-c by ICS,
ELISA titers or IFA titers after the first and second immunizations
(Table S2, section A). There were no significant correlations
between pre-existing NAb titers and these immune measures. This
was also true when correlations were performed between vaccine-
induced NAb titers (measured just prior to the second immuni-
zation) and the same immune measures after the second
immunization (Table S2, section B), although there was a non-
significant trend for a negative effect on CD4+ T cells. The lack of
an effect on immunogenicity (other than for CD4+ T cells) was
particularly striking after the second immunization, as very high
anti-Ad5 antibody activities were induced by the first immuniza-
tion in some volunteers (Figure 10).
However, when fold changes in titers were correlated rather
than the titers themselves, the fold-increase in NAb titer
(calculated as titer prior to the second immunization divided by
titer prior to the first immunization) showed a highly statistically
significant negative correlation with the fold change in ELISA
(calculated as titer following the second immunization divided by
titer following the first immunization, a figure that in half the
volunteers was less than 1 meaning that the second immunization
did not further improve titers) (r =20.76, p = 0.0062) (Table S2,
section C). A marginally non-significant negative correlation was
seen with IFA (r =20.57, p = 0.069). However, no negative
association was seen with ELISpot (r = +0.24, p = 0.48), nor with
Figure 3. Neutrophil Kinetics Group 3. A fall in neutrophil count
was observed in most volunteers at 2–3 days post-immunization with
return to normal or near normal levels by day 7 post-immunization after
the 1st and 2nd immunization. Day 0 for the 2nd immunization is 15
weeks after the 1st immunization. Dotted line indicates normal levels.
doi:10.1371/journal.pone.0025868.g003
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ICS CD4+ and CD8+ T cell IFN-c responses, indicating that, like
absolute titers of NAb, fold change in NAb had no influence on
CMI responses in this trial.
Interestingly, the four individuals with pre-existing titers ,12
were the four with the greatest fold increase in NAb after the first
immunization and three of the four showed the poorest antibody
responses to the second dose of vaccine (Figure 11, points
indicated with dashed circles). Conversely, the four volunteers
with the highest pre-existing titers (.500) tended to show the least
fold increases in NAb titers (Figure 11, points indicated with solid
circles), and this was associated with improved induction of
antibody responses following the second immunization. Overall,
fold increase in NAb after the first immunization was negatively
associated with fold change in antibody responses, comparing
responses after the second immunization to responses after the
first.
Relationship between immunogenicity and efficacy
When pre-challenge T cell responses by ELISpot and antibody
titers by ELISA and IFA assays were compared to time to patency
(Figure 12), there was no association between any of these
measures and time to parasitemia ((p.0.1 for each predictor). The
same was true for CD4+ and CD8+ T cell populations (p.0.1).
When pre-challenge ELISpot responses to individual CSP peptide
pools (Cp1–Cp9) were examined, one volunteer (v69) who became
patent at 16 days was characterized by exceptionally strong
ELISpot responses to one CSP peptide pool (Cp1) that were 2-fold
greater than the next closest volunteer (v40), who did not have a
significant delay of patency (Figure 12, lower panel). Therefore it is
possible these T cell responses to Cp1 may have contributed to
delayed patency in this volunteer. However, ELISpot responses in
v45, who also had delayed parasitemia, were low. Thus there was
no clear association between pool-specific responses and delay in
parasitemia.
Discussion
Interpretation
Safety. The first objective of this study was to assess the safety
and reactogenicity of the NMRC-MV-Ad-PfC vaccine. NMRC-
MV-Ad-PfC (CSP component of parent vaccine NMRC-M3V-
Ad-PfCA) given in two doses of 161010 pu was safe and well
tolerated. The withdrawal of one volunteer after the first
immunization was not vaccine-related. A second volunteer, with
a history of migraine headaches, developed a migraine eight hours
after the second immunization, possibly triggered by vaccine
Figure 4. ELISpot IFN-c CSP. The ELISpot activity of each volunteer at pre-immunization, 1 month and 15 weeks after the first immunization, 19
days after the second immunization, and 21 days after challenge (* this last data point not available for volunteer 41), as stacked, color-coded peptide
pool-specific responses at each time point. The insert shows the values of the sum of pool-specific responses for each volunteer at each time point.
The horizontal bar indicates the geometric mean of the group, the arrows indicate the first and second immunizations and challenge, and the percent
of volunteers who were positive with at least one CSP pool at each time point is written at the top of the insert.
doi:10.1371/journal.pone.0025868.g004
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administration, and was excluded from participation in the
malaria challenge. Pre-existing anti-Ad5 antibodies have been
associated with decreased frequency of systemic AEs in other
clinical trials [62], but no association could be determined
comparing the reactogenicity profiles of seronegative and
seropositive volunteers in this study.
When results from Group 3 and Groups 1 and 2 (Sedegah et al)
were analyzed together the frequency of local adverse events were
similar among the groups, However there were more systemic AEs
in the high dose Group 2 volunteers (22 systemic AEs in six
volunteers in six doses of vaccine; 3.7/vol/dose) than in low dose
Group 1 volunteers (nine systemic AEs in six volunteers in six
doses; 1.5/vol/dose) or low dose Group 3 volunteers (15 systemic
AEs in 15 volunteers in 29 doses; 0.5/vol/dose). When pain or
tenderness at the injection site, objective fever, myalgia, malaise
and headache were examine separately from the other AE’s, the
AE rates between groups were statistically significantly different
(Figure 2). An increasing incidence of adverse events related to
dose has been recorded in other adenovectored vaccine trials,
where a similar range of doses was administered [62,64].
Neutropenia was the only apparent vaccine-related laboratory
abnormality. Serotype 5 adenoviruses are thought to activate toll-
like receptor 9 (TLR9) on dendritic cells [65]. When CpG, an
immunostimulatory TLR9 agonist, was injected into human
volunteers[66,67] or injected with a malaria vaccine[68], it
induced a transient neutropenia and injection site reactions that
were linked to stimulation of the innate immune system and
associated white blood cell sequestration[68]. Therefore, it is
possible that the vaccine induced neutropenia through TLR9. As
with CpG, neutropenia resolved within a week in most volunteers
and did not appear to present any clinical risk.
Immunogenicity. The second objective of this study was to
evaluate the immunogenicity of the NMRC-MV-Ad-PfC vaccine.
In the first study of the parent vaccine (Sedegah et al), the lower
vaccine dose (161010 pu) induced statistically significantly better
ELISpot responses than the five-fold higher dose (561010 pu each
construct), and for this reason the lower dose was selected for
administration of NMRC-MV-Ad-PfC to Group 3. All volunteers
developed increased ELISpot and antibody responses after the first
immunization that generally peaked at 28 days, drifted down
during the next 15 weeks and were boosted following the second
immunization but generally did not exceed responses induced by
the first immunization. IFN-c responses to CSP as measured by
ELISpot assay were in most cases robust, ranging in strength from
51 to 1128 sfc/m PBMCs, and were comparable to those induced
by the RTS,S vaccine[69]. Although CD4+ T cell responses
measured by ICS were lower than those reported in a recent
RTS,S vaccine trial[69], RTS,S does not concurrently induce the
robust CD8+ T cell responses recorded in this trial[70]. In
contrast, antibody levels were low compared to those induced by
Figure 5. ICS CD4+ and CD8+ T cell IFN-c CSP responses. Percent CD4+ and CD8+ T cells secreting IFN-c in response to CSP for each volunteer
at each time point, color-coded by peptide pool. The percents at each time point are plotted for each volunteer along with the geometric means for
the group (horizontal bars). Responses prior to immunization are subtracted from all data in order to show only vaccine-induced responses.
doi:10.1371/journal.pone.0025868.g005
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RTS,S [15,69,71] and the kinetics of responses were different as at
least two doses of RTS,S are generally required for maximum
antibody responses [71], whereas a single dose of NMRC-MV-Ad-
PfC induced peak responses in most volunteers.
Other clinical trials, in which two or more doses of
adenovectored vaccines have been given, showed results consistent
with this study. Repeat doses of adenovectored vaccines such as
one encoding HIV gag (161010 pu dose) have been given at four
weeks but have not significantly boosted responses over those
induced by the first immunization [72,73]. Likewise, a repeat dose
of an adenovectored vaccine administered at three months did not
improve responses to human cystic fibrosis [CF] transmembrane
regulator relative to the first dose [74]. In that study, volunteers
developed high titers of NAb after the first immunization, which
was hypothesized to have affected the immunogenicity of the
second dose.
Flow cytometry showed a predominance of CD8+ over CD4+ T
cell IFN-c responses for most (but not all) volunteers, as has been
seen in other studies of adenovirus-vectored vaccines in
humans[72] (Figure 5). IFN-c single secretors were by far the
most abundant phenotype among IFN-c-secreting CD8+ T cells,
indicating that the vaccine was a strong inducer of CD8+ effector
T cells, but IFN-c single secretors constituted only about half the
population of IFN-c-secreting CD4+ T cells (Figure 6). The T cell
subpopulations secreting both IFN-c and IL2 were negligible for
both CD4+ and CD8+ T cells. The second immunization did not
affect IFN-c production as strongly as the first immunization;
however, IFN-c responses were remarkably sustained, especially
for CD8+ T single secretors, which persisted strongly 12 weeks
post challenge.
Proportions of T cells secreting IL-2 increased after the second
immunization for both CD4+ and CD8+ T cells, to levels similar
or higher that after the first, consistent with requirement for
larger quantities of antigen to induce IL-2 compared with IFN-c
secretion. Thus a second dose of vaccine did not appear to be
driving lymphocyte populations to a terminal single-secreting
effector phase [73,75]. On the contrary, the increase in IL2
secretion following the second immunization may reflect a
strengthened reservoir of memory CD4+ T cells, and may have
contributed to the sustained CD4+ T cell and CD8+ T cell IFN-
c responses mentioned above [75]. In the case of TNF-a, TNF-
a-secreting CD4+ T cells appeared unaffected by the second
immunization, whereas TNF-a-secreting CD8+ T cells increased
along with the IL-2-secreting CD8+ cells. TNF-a-secreting
CD8+ T cells fell during the ensuing weeks, whereas IL-2-
secreting CD8+ cells were relatively sustained. The peaking of
CD8+ T cell IL2 responses after CD8+ T cell TNF-a responses
is consistent with a hierarchical control of CD8 + T cell cytokine
responses seen in murine studies[75]. Triple-secreting T cells
subpopulations occurred as a small percentage of both CD4+
and CD8+ T cells (Figure 6, and Supplementary Figure S1);
interestingly, the two volunteers with delayed onset of parasit-
emia were among the three with the highest frequencies of
multiply-positive CD8+ T cells. The evolution of different single
and multifunctional CD4+ and CD8+ T cells subpopulations in
response to NMRC-MV-Ad-PfC vaccine deserves further study
and analysis.
Pre-existing and vaccine-induced Nab. Four of eleven
volunteers evaluated for immunogenicity lacked any evidence of
prior exposure to Ad5 (titers ,12), while three had moderate titers
(.12, ,500) and four had high titers (.500). Contrary to
expectations, naturally-acquired NAb had no appreciable effect on
IFN-c responses by ELISpot or ICS, or antibody responses by
CSP ELISA or sporozoite IFA, as measured after the first or
second doses of vaccine (Table S2, section A). Following the first
immunization, however, the four seronegative volunteers
Figure 6. ICS CD4+ and CD8+ T cell multifunctional CSP responses. Arithmetic group mean percents with standard error of the mean for all
cytokine phenotypes (total IFN-c, total IL-2 or total TNF-a in bold solid lines, only IFN-c, only IL2 or only TNF-a in dotted lines, and other subsets as
non-bold solid lines). Responses prior to immunization are subtracted from all data in order to show only vaccine-induced responses.
doi:10.1371/journal.pone.0025868.g006
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Figure 7. CSP ELISA and Sporozoite IFA activity. Box plots of the medians (50th percentile) and 25th and 75th percentiles of ELISA and IFA
activities prior to immunization, at 1 month and 15 weeks after the first immunization, 19 days after the second immunization, and 21 days after
challenge. Whiskers spanning the first and third quartiles are at the base and top of each box, respectively, while the upper and lower horizontal bars
at the ends of the whiskers represent the maximum and minimum values, respectively. Outliers are depicted by black dots; the arrow points to an
outlier above the scale of the chart (1/20,480). The numbers give the value of the medians of each box, which in some cases are the same as the 25th
or 75th percentile. When pre-challenge and post challenge titers were compared, ELISA remained similar (p = 0.15) but titers significantly increased for
IFA (p = 0.02) using repeated analysis of log transformed values.
doi:10.1371/journal.pone.0025868.g007
Figure 8. Comparing Groups 1, 2 and 3 for Immune Outcome Measures. The geometric means of ELISpot assay (CSP), ELISA (CSP) and IFA
(sporozoite) in Groups 1, 2 and 3 are shown pre-immunization (Pre) and 1 and 4 months post immunization (1 month and 15 weeks post first
immunization for Group 3). Groups 1 and 3 had better ELISpot responses than Group 2 (high dose), while Group 2 had the better ELISA and IFA
responses (see Sedegah et al). Combination of the vector encoding CSP with the vector encoding AMA1 (Group 1) may have improved responses to
CSP relative to the vector encoding CSP administered alone (Group 3), as immune responses were higher in Group 1 than in Group 3 for the three
immune measures.
doi:10.1371/journal.pone.0025868.g008
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experienced sharp increases in NAb titers compared to the
seropositive volunteers (Figure 10). Although the resulting NAb
titers again had no significant associations with measures of
immunogenicity following the second immunization (Table S2,
section B), three of the four originally seronegative individuals
showed the poorest boosting of antibody responses to CSP
following the second immunization among the eleven volunteers
studied, while the originally seropositives individually boosted
relatively well (Figure 10). In contrast with antibody responses, fold
increase in NAb was not associated with positive or negative effects
on ELISpot or ICS responses.
These differences likely reflect differential effects of naturally-
acquired and vaccine-induced antibodies on the immune respons-
es to the CSP transgene. A recent clinical study indicated that
naturally-induced neutralizing antibodies were primarily directed
to the Ad5 fiber whereas immunization with an adenovector
induced neutralizing antibodies primarily directed to non-fiber
capsid proteins (e.g., Ad5 hexon) [76]. The specificity of antibodies
to various capsid proteins could variously affect trafficking and
uptake of the vector by different cells types or tissues following
vaccine administration, such that humoral but not cell-mediated
responses were impacted. Antibodies to hexon protein, for
Figure 9. Vaccine Efficacy by Kaplan-Meier Plot. Two immunized volunteers became parasitemic on day 16, more than 2 standard deviations
beyond the geometric mean time for the infectivity controls (day 13), indicating a significant delay. When days to patency were compared between
the immunized and control groups, there was no difference observed (p = 0.46).
doi:10.1371/journal.pone.0025868.g009
Figure 10. Anti-Ad5 NAb titers. Anti-Ad5 neutralization titers were measured pre-immunization (Pre) and 1 month and 15 weeks post 1st
immunization and 19 days post 2nd immunization. Volunteers are shown in color-coded lines. Right Panel: median NAb titers of volunteers with high
(.500), low (12–500) or absent (,12) titers at the time of enrolment.
doi:10.1371/journal.pone.0025868.g010
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example, could lead to viral uptake by APC’s and differentially
affect class I vs. class II presentation. It is possible that non-
neutralizing anti-adenovirus antibodies may also modulate
immune responses. As another possible mechanism, homing
patterns of vaccine-induced T cells, could be affected by the type
of pre-existing NAb, as was shown in a study in chimpanzees [77].
Various approaches to overcome the effects of neutralizing
antibodies include replacing the hypervariable region of the
adenovirus capsid with a malaria CSP sequence circumvented
neutralization by pre-existing anti-adenovirus antibodies while
maintaining immunogenicity[62]
Other studies suggest that the effect of pre-existing antibody on
immune responses may be at least partially antigen dependent. In
a study of an adenovectored HIV vaccine, ELISpot responses to
gag but not to env appeared to be negatively affected by pre-
existing immunity[62].
Interference. The immunogenicity of the CSP-encoding
adenovector was similar in magnitude whether administered
alone or mixed at the same dose with the AMA1-encoding
adenovector (comparing the first dose in Group 3 with Group 1).
Studies of mixtures of gene-based vaccines have shown that while
many antigens may be compatible, some markedly inhibit the
immunogenicity of other antigens[78,79]. In this study, the
combination of CSP with AMA1 had no negative impact on the
immunogenicity of CSP. On the contrary, the double dose of
adenovector in Group 1 compared with Group 3 may have
provided a degree of non-specific immune stimulation since there
was a non-significant trend toward improved immunogenicity in
the mixture, consistent with findings that adenoviral vectors may
activate innate and adaptive immune responses via the TLR9 or
other receptors[79,80,81].
Efficacy. The third objective was to determine whether
NMRC-MV-Ad-PfC provided protection against experimental
P. falciparum sporozoite challenge. The CSP component was
studied by itself in order to compare results with the protective
RTS,S vaccine. No volunteer was protected, although two of 11
volunteers showed a delay to patency according to an accepted
measure [71,82]. Further evaluation of the immune responses
elicited by these two volunteers revealed high levels of IFN-c to
CSP peptide pool Cp1 in one of these volunteers (two fold higher
than in any other volunteer), but low responses in the other,
precluding any clear association between these responses and
delay. Interestingly, these two volunteers were among the three
volunteers showing the highest frequencies of multifunctional
CD8+ T cells.
Adenovirus-vectored P. yoelii CSP induced sterile immunity in
40% of immunized mice and reduced liver stage parasite load in
the remaining mice by up to 93% resulting a prolonged pre-patent
period [53]. Therefore, the partial protection seen in this clinical
trial could be interpreted as consistent with the murine study, since
the delay to parasitemia in two volunteers may also have resulted
from a reduction in the numbers of liver stages by vaccine-induced
CD4+ and/or CD8+ T cells.
The results of this study contrast with the RTS,S vaccine, also
based on CSP, that sterilely protects roughly 41% of malaria-naı¨ve
volunteers against experimental sporozoite challenge when adju-
vanted with AS02 [71]. RTS,S induces high antibody responses and
CD4+ T cell responses that have been correlated with protec-
tion[69]. In this study, the magnitudes of antibody and CD4+ T cell
responses elicited by the NMRC-MV-Ad-PfC vaccine were likely
insufficient to reproduce the protective mechanism of RTS,S. Even
though robust CD8+ T cell responses were induced, they may
likewise have been insufficient to induce protection via cell-
mediated cytotoxicity. Prolonged antigen loads may affect CD8+
T cell responses and perhaps, therefore, is a consequence of two
immunizations with the NMRC-MV-Ad-PfC vaccine[83,84],
suggesting that the quality rather than quantity of CD8+ T cell
may be as important in mediating protection. Therefore, it would be
useful to test heterologous prime-boost regimens able to induce
higher levels of CMI, and to include additional pre-erythrocytic
stage antigens in the vaccine to see if the adenovirus platform is
more suitable for antigens other than CSP.
Generalizability
The favorable tolerability and safety profile of the NMRC-MV-
Ad-PfC vaccine is consistent with other studies of Ad5 vaccines
Figure 11. Negative Correlation between Fold Increase in Ad5 NAb Titer and Fold Change in CSP ELISA Titer. The ratio between Ad5
NAb titers induced by the first immunization (measured at 1 month) and titers prior to the first immunization (fold increase) was negatively correlated
with the ratio between CSP ELISA titers induced by the second immunization (at 19 days) and titers induced by the first (at 1 month) (fold change).
Volunteers with absent pre-existing immunity prior to the first immunization (titer,12, dotted circles) showed the greatest fold increase in NAb and,
overall, the poorest boosting of antibody responses to CSP, while the volunteers with the highest pre-existing immunity (titer .500) (solid circles)
showed the least fold increases in NAb and, overall, better boosting of antibody responses.
doi:10.1371/journal.pone.0025868.g011
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encoding non-malarial antigens administered at similar doses.
Likewise, the immunogenicity recorded in this trial is concordant
with other trials of Ad5-vectored vaccines.
The absence of sterile protection following immunization with
NMRC-MV-Ad-PfC may be related to the antigen studied or to
the delivery system. Other malaria antigens, particularly other
liver stage antigens, should be tested, as well as prime-boost
approaches. These strategies may augment T cell and antibody
responses, and may also improve the quality of the T cell response
to protect. For example, prime-boost approaches have been shown
to increase the magnitude of both antibody and T cell responses
and may induce different epitope specificities, or different cytokine
profiles in the responding T cells.
Limitations
The small sample size of this first-in-humans study limits the
power to draw firm conclusions regarding the impact of NAb on
the immunogenicity of the vaccine: seven volunteers had titers
,500, and four volunteers had titers .500. Nevertheless, results
from these 11 volunteers demonstrated a divergent effect of NAb
on humoral and cell-mediated responses. The data indicated that
an absence of pre-existing NAb led to stronger vaccine-induced
NAb which may have subsequently blunted the humoral response
to a second dose of vaccine, whereas ELISpot responses were
unaffected. However, these results need confirmation. In partic-
ular, more data are needed to differentiate the effects of naturally-
acquired vs. vaccine-induced NAb, and to document whether or
not the effects of pre-existing immunity are antigen-dependent.
Overall evidence
This trial confirms other studies demonstrating the safety and
tolerability of adenovector vaccines in the 1610102161011 pu
dose range, provides additional evidence of the potency of
adenovectors for inducing CD8+ IFN-c responses targeting
malaria antigens in humans, suggests that a second dose does
not enhance the immunogenicity of a first dose, and that CSP does
not offer significant protection when delivered by itself using an
Ad5 platform. Improved efficacy against P. falciparum may be
achieved by employing heterologous prime-boost strategies or by
adding other malaria antigens to the vaccine.
Supporting Information
Figure S1 ICS CD4+ and CD8+ multicytokine T cell
responses (CSP). Panels A & C: Multifunctional (any two or
more cytokines among IFN-c, IL2 or TNF-a) CD4+ and CD8+ T
cell activity of each volunteer in response to CSP peptides at (1) 1
month and (2) 15 weeks after the first immunization, (3) 19 days
after the second immunization, and (4) 21 days after challenge, as
stacked, color-coded peptide pool-specific responses at each time
point. Responses prior to immunization were subtracted in order
to show only vaccine-induced responses. Panels B & D: Pie charts
representing the proportion of secreting cells that were single
cytokine secretors, double cytokine secretors or triple cytokine
secretors; numbers on pie charts represent percents. Panel E: The
values of the sum of pool-specific responses for each volunteer at
each time point listed in Panels A and C plus and additional time
point 12 weeks post challenge. The horizontal bar indicates the
geometric mean of the group.
(TIF)
Table S1 Unsolicited adverse events definitely, proba-
bly or possibly related to immunization. Unsolicited
adverse events were recorded for 28 days following each
immunization.
(DOC)
Table S2 Rank correlations between pre-existing and
vaccine-induced anti-Ad5 NAb titers and CSP ELISpot,
CD4+ T cell and CD8+ T cell IFN-c activities and CSP
ELISA and Sporozoite IFA titers post 1st and 2nd
immunizations. A: Pre-existing Ad5 NAb titers measured prior
to the first immunization were tested to see if they were correlated
with CSP IFN-c ELISpot, total IFN-c CD4+ T cells by ICS, total
IFN-c CD8+ T cells by ICS, CSP ELISA and sporozoite IFA
activities for 11 volunteers in Group 3 for both the first and second
immunizations. The upper number in each paired entry is the
rank correlation coefficient (r) and the lower number is the p-value
for the null hypothesis that the correlation is zero. No significant
correlations were identified. B: Vaccine-induced Ad5 NAb titers
measured prior to the second immunization were correlated with
the same immune measures after the second immunization. Again,
no significant correlations were identified, although there was a
trend toward a negative effect on CD4+ T cells (p = 0.089). C: The
fold-increases in Ad5 NAb titers from before the first to before the
second immunization were calculated, and correlations were
computed. There were no significant correlations identified with
Figure 12. Relationship between pre-challenge ELISA (CSP),
IFA (sporozoite) and ELISpot (CSP) activities and time to
patency after challenge. Upper Panel: The time to patency in days
after sporozoite challenge was compared to the pre-challenge
magnitude of three immune measures: ELISA (CSP), IFA (sporozoite)
and ELISpot (CSP). Best-fit trendlines are plotted with r2 values shown.
There was no correlation between immune measures and time to
patency. Lower Panel: Volunteers are arrayed according to time to
patency (labeled in days at the top of each column), showing ELISpot
activity to each color-coded CSP peptide pool. There is no evident
relationship between magnitude of pool-specific or summed responses
and time to patency.
doi:10.1371/journal.pone.0025868.g012
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the same immune measures after the first or second immuniza-
tions, but when fold changes were calculated in these immune
measures (fold changes from activities one month following the
first immunization to activities 19 days following the second
immunization), a highly significant negative correlation was
identified for ELISA (bold) and a non-significant trend for IFA
(p = 0.0686). This correlation for ELISA is shown graphically in
Figure 7. In contrast, no association was evident for ELISpot
responses, CD4+ T cell responses or CD8+ T cell responses, for
which correlation coefficients were positive and non-significant.
Rank correlation coefficients and p-values were obtained from
SAS.
(DOC)
Protocol S1
(DOC)
Checklist S1
(DOC)
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